Biomarker ID | 1463 |
PMID | 25057439 |
Year | 2014 |
Biomarker | High Mobility Group Box 1 (HMGB1) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Stage T3-T5 |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include: Endogenous Toll-like receptor signaling, Interferon-beta enhancer pathway, Base excision repair, Beta-3 integrin cell surface interactions, TAK1 activates NF-kappaB by phosphorylation and activation of IKK complex |
Experiment | stage T1-T2 Vs Stage T3-T4 |
Type of Biomarker | Prognostic |
Cohort | 85 patients with prostate cancer and 30 with Benign prostatic hyperplasia were selected for the analysis. 36 had Stage T1-T2 and 49 had Stage T3-T4 |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.009 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |